World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
81
Citations
33681
World Ranking
16422
National Ranking
648

Massimo Federico publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Massimo Federico sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 626 publications — 74th percentile

74% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Massimo Federico D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Massimo Federico sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 81 D-Index — 19th percentile

19% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Massimo Federico is affiliated with the University of Modena and Reggio Emilia in Italy. Their research primarily focuses on medical science, with a substantial body of work in pathology and forensic medicine, oncology, pulmonary and respiratory medicine, genetics, and neurology.

The scientist has published extensively across a variety of specific topics including lymphoma diagnosis and treatment, lung cancer treatments and mutations, viral-associated cancers and disorders, chronic lymphocytic leukemia research, CNS lymphoma diagnosis and treatment, ovarian cancer diagnosis and treatment, and CAR-T cell therapy research.

Frequent publication venues for their work include:

  • Hematological Oncology
  • Blood
  • HemaSphere
  • Journal of Clinical Oncology
  • British Journal of Haematology

Among their recent published papers are:

  • Survival outcomes of patients with extranodal natural-killer T-cell lymphoma: a prospective cohort study from the international T-cell Project, 2020, The Lancet Haematology
  • Outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma: final report from the international T-cell Project, 2021, Blood
  • Response-Adapted Postinduction Strategy in Patients With Advanced-Stage Follicular Lymphoma: The FOLL12 Study, 2021, Journal of Clinical Oncology
  • Brentuximab Vedotin Plus AVD for First-Line Treatment of Early-Stage Unfavorable Hodgkin Lymphoma (BREACH): A Multicenter, Open-Label, Randomized, Phase II Trial, 2022, Journal of Clinical Oncology
  • Long-term overall survival and toxicities of ABVD vs BEACOPP in advanced Hodgkin lymphoma: A pooled analysis of four randomized trials, 2020, Cancer Medicine

Massimo Federico collaborates frequently with several co-authors who have contributed to numerous publications alongside them. Notable co-authors include:

  • Martina Manni
  • Stefano Luminari
  • Tetiana Skrypets
  • Luigi Marcheselli
  • Yana Stepanishyna

Best Publications

  • Revised response criteria for malignant lymphoma

    Bruce D. Cheson;Beate Pfistner;Malik E. Juweid;Randy D. Gascoyne

  • Follicular lymphoma international prognostic index.

    Philippe Solal-Céligny;Pascal Roy;Philippe Colombat;Josephine White

  • Magnetic resonance imaging of the breast: recommendations from the EUSOMA working group.

    Francesco Sardanelli;Carla Boetes;Bettina Borisch;Thomas Decker

  • Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts

    Heikki Joensuu;Aki Vehtari;Jaakko Riihimäki;Toshirou Nishida

  • Follicular Lymphoma International Prognostic Index 2: A New Prognostic Index for Follicular Lymphoma Developed by the International Follicular Lymphoma Prognostic Factor Project

    Massimo Federico;Monica Bellei;Luigi Marcheselli;Stefano Luminari

  • Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin’s Lymphoma

    Peter Johnson;Massimo Federico;Amy A Kirkwood;Alexander Fossa

  • Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study

    Andrea Gallamini;Caterina Stelitano;Roberta Calvi;Monica Bellei

  • Early Positron Emission Tomography Response-Adapted Treatment in Stage I and II Hodgkin Lymphoma : Final Results of the Randomized EORTC/LYSA/FIL H10 Trial

    Marc P. E. Andre;Theodore Girinsky;Massimo Federico;Oumedaly Reman

  • Randomized Comparison of Gemcitabine, Dexamethasone, and Cisplatin Versus Dexamethasone, Cytarabine, and Cisplatin Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed and Refractory Aggressive Lymphomas: NCIC-CTG LY.12

    Michael Crump;John Kuruvilla;Stephen Couban;David A. MacDonald

  • Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project

    Dennis D. Weisenburger;Kerry J. Savage;Nancy Lee Harris;Randy D. Gascoyne

  • Omitting Radiotherapy in Early Positron Emission Tomography–Negative Stage I/II Hodgkin Lymphoma Is Associated With an Increased Risk of Early Relapse: Clinical Results of the Preplanned Interim Analysis of the Randomized EORTC/LYSA/FIL H10 Trial

    John M M Raemaekers;Marc P E André;Massimo Federico;Theodore Girinsky

  • Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    D. A. Eichenauer;A. Engert;M. André;M. Federico

  • Multicenter Comparative Multimodality Surveillance of Women at Genetic-Familial High Risk for Breast Cancer (HIBCRIT Study): Interim Results

    Francesco Sardanelli;Franca Podo;Giuliano D'Agnolo;Arduino Verdecchia

  • Multicenter Surveillance of Women at High Genetic Breast Cancer Risk Using Mammography, Ultrasonography, and Contrast-Enhanced Magnetic Resonance Imaging (the High Breast Cancer Risk Italian 1 Study): Final Results

    Francesco Sardanelli;Franca Podo;Filippo Santoro;Siranoush Manoukian

  • Clinicopathologic Characteristics of Angioimmunoblastic T-Cell Lymphoma: Analysis of the International Peripheral T-Cell Lymphoma Project

    Massimo Federico;Thomas Rudiger;Monica Bellei;Bharat N. Nathwani

  • Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma

    Sally F. Barrington;Wendi Qian;Edward J. Somer;Antonella Franceschetto

  • International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017)

    A Younes;P Hilden;B Coiffier;A Hagenbeek

  • ABVD Compared With BEACOPP Compared With CEC for the Initial Treatment of Patients With Advanced Hodgkin's Lymphoma: Results From the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial

    Massimo Federico;Stefano Luminari;Emilio Iannitto;Giuseppe Polimeno

  • Enteropathy-associated T-cell lymphoma: clinical and histological findings from the international peripheral T-cell lymphoma project.

    Jan Delabie;Harald Holte;Julie M. Vose;Fred Ullrich

  • Splenic marginal zone lymphoma: a prognostic model for clinical use

    Luca Arcaini;Mario Lazzarino;Nora Colombo;Sara Burcheri

Frequent Co-Authors

Umberto Vitolo
Umberto Vitolo University of Turin
Pier Luigi Zinzani
Pier Luigi Zinzani University of Bologna
Antonino Neri
Antonino Neri University of Milan
Francesco Di Raimondo
Francesco Di Raimondo University of Catania
Pellegrino Musto
Pellegrino Musto University of Bari Aldo Moro
Gianluca Gaidano
Gianluca Gaidano University of Eastern Piedmont Amadeo Avogadro
Emanuele Zucca
Emanuele Zucca Universita della Svizzera Italiana
Stefano Pileri
Stefano Pileri European Institute of Oncology
Manlio Ferrarini
Manlio Ferrarini University of Genoa
Rosario Tumino
Rosario Tumino Provincial Health Authority of Syracuse

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you're exploring medicine in the USA, several alternative online pathways can help launch your healthcare career. For those interested in advanced nursing but without prior nursing experience, direct entry online MSN programs allow you to earn a master's degree and fast-track into the field.

Prospective students seeking greater accessibility can consider applying to nursing programs with high acceptance rates. These schools can offer more entry points into nursing for those concerned about competitiveness.

For those interested in administrative roles, the best online medical billing and coding schools provide flexible online training and may also offer financial aid. This is an excellent option for students wanting a healthcare career outside of direct patient care.

Additionally, students can find nursing school no entrance exam options. These programs do not require TEAS or HESI exams, making it easier for many to start their journey in nursing and healthcare.

Best Scientists Citing Massimo Federico

Trending Scientists

Recently Published Articles